Table 2.

Distribution of patient characteristics and lipid-lowering drug exposure among all case and control patients and their association with VTE risk in multivariate analysis.

	Case (n = 72)	Control (n = 432)*	Unadjusted odds ratio (95% CI)	Adjusted odds ratio (95% CI)
Age (years)
40–49	10 (13.9%)	56 (13.0%)	–	–
50–59	23 (31.9%)	140 (32.4%)	–	–
60–69	23 (31.9%)	150 (34.7%)	–	–
70–79	16 (22.2%)	86 (19.9%)	–	–
Sex
;Male	36 (50.0%)	216 (50.0%)	–	–
Female	36 (50.0%)	216 (50.0%)	–	–
Smoking
Nonsmoker	41 (56.9%)	221 (51.2%)	–	–
Current	17 (23.6%)	71 (16.4%)	1.4 (0.7, 2.7)	2.0 (1.0, 4.4)
Ex-smoker	6 (8.3%)	70 (16.2%)	0.4 (0.2, 1.1)	0.4 (0.2, 1.1)
Unknown	8 (11.1%)	70 (16.2%)	0.6 (0.2, 1.3)	1.2 (0.4, 3.8)
Body mass index (kg/m2)
< 25.0	19 (26.4%)	123 (28.5%)	–	–
25.0–29.9	25 (34.7%)	130 (30.1%)	1.2 (0.6, 2.3)	1.9 (0.9, 3.7)
≥ 30.0	17 (23.6%)	65 (15.1%)	1.7 (0.8, 3.6)	2.5 (1.1, 5.7)
Unknown	11 (15.3%)	114 (26.4%)	0.6 (0.3, 1.3)	0.6 (0.2, 1.7)
Oestrogen use
None	52 (72.2%)	366 (84.7%)	–	–
Current	15 (20.8%)	40 (9.3%)	5.3 (2.1, 13.6)	6.5 (2.4, 17.9)
Past	5 (6.9%)	26 (6.0%)	2.3 (0.7, 7.7)	2.3 (0.7, 7.7)
Exposures of interest
Normolipidaemic nonuse	59 (81.9%)	329 (76.2%)	–	–
Current/recent statin use	3 (4.2%)	18 (4.2%)	0.9 (0.3, 3.4)	1.1 (0.3, 4.3)
Past statin use	2 (2.8%)	5 (1.2%)	2.0 (0.3, 11.3)	3.7 (0.6, 24.1)
Current/recent other	0 (0.0%)	12 (2.8%)	–	–
lipid-lowering drug use
Past other lipid-lowering drug use	2 (2.8%)	6 (1.4%)	1.8 (0.3, 9.5)	2.0 (0.3, 11.6)
Mixed use	0 (0.0%)	6 (1.4%)	–	–
Hyperlipidaemic nonuse	6 (8.3%)	56 (13.8%)	0.6 (0.2, 1.5)	0.4 (0.2, 1.2)

^*Including 355 controls from the same general practice, and 77 controls selected from the other practices.